Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical sintilimab with concurrent chemoradiotherapy and neutron brachytherapy for first-line advanced gynecologic squamous cell carcinoma
ChiCTR2300074868Phase 2Completed
- Sponsor
- Heilongjiang Provincial Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in Gynecologic Squamous Cell Carcinoma, cervical squamous cell carcinoma (CSCC), vaginal squamous cell carcinoma (SCCV) and 1 more, sponsored by Heilongjiang Provincial Hospital. Started Jan 2021; status: completed.
02
Drugs
sintilimab
03
Conditions
Gynecologic Squamous Cell Carcinomacervical squamous cell carcinoma (CSCC)vaginal squamous cell carcinoma (SCCV)vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on ChiCTR2300074868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074868.